Time to shine for constrained peptides as next-generation pharmaceuticals

限制肽作为下一代药物大放异彩的时刻到了

• 批准号: FT220100010
• 负责人: A/Prof Christoph Nitsche
• 金额: $ 55.9万
• 依托单位: The Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: ARC Future Fellowships
• 财政年份: 2023
• 资助国家: 澳大利亚
• 起止时间: 2023-05-01 至 2027-04-30
• 项目状态: 未结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/FT220100010
• 关键词: Time; shine; constrained; peptides; next

Current methods for the screening and generation of peptide and protein drugs are laborious, expensive and often incompatible with the biological systems used in pharmaceutical industries. Leveraging recent advancements in chemistry and molecular biology, this project aims to improve the design, synthesis and screening of peptide-based pharmaceuticals. Key research outcomes are innovative biocompatible chemical transformations for the screening of large peptide libraries, to unleash the revolutionary potential of constrained peptides in drug development. Expected benefits are reliable and cost-effective technologies for the rapid production of biologically active molecules for future targeted use in human and agricultural pharmaceuticals.

目前用于筛选和产生肽和蛋白质药物的方法是费力的、昂贵的，并且通常与制药工业中使用的生物系统不相容。利用化学和分子生物学的最新进展，该项目旨在改进基于肽的药物的设计，合成和筛选。主要研究成果是用于筛选大型肽库的创新生物相容性化学转化，以释放药物开发中受限肽的革命性潜力。预期收益是快速生产生物活性分子的可靠和具有成本效益的技术，以便将来有针对性地用于人类和农业制药。